1809010-50-1
1809010-50-1
Chemical Structure
Berotralstat
Synonym(s): BCX7353
- CAS No.: 1809010-50-1
- Formula:C30H26F4N6O
- Molecular Weight:562.56
IUPAC Name: (R)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
InChIKey: UXNXMBYCBRBRFD-MUUNZHRXSA-N
SMILES: O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F
Biological Activity: Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Berotralstat | 98.73% | Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Berotralstat (Standard) | ≥98% | Berotralstat (Standard) is the analytical standard of Berotralstat. This product is intended for research and analytical applications. Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Berotralstat-d4-1 | Berotralstat-d4-1 (BCX7353-d4-1) is the deuterium labeled Berotralstat (HY-109127). Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6. [Content Brief]
- [2]. Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5(3), 223-233.
